Skip to main content

ESTUDIO DE LOS MECANISMOS MOLECULARES QUE REGULAN LOS PROCESOS DE RECONOCIMIENTO DE ANTIGENO Y ACTIVACION DE LOS LINFOCITOS B MEDIANTE LA ALTERACION DE LA DINAMICA CELULAR

BFU2011-30097

•
Funding agency name Ministerio de Ciencia e Innovación
Funding agency acronym MICINN
Program Programa Nacional de Proyectos de Investigación Fundamental
Subprogram Subprograma de Proyectos de Investigación Fundamental no Orientada
Call Proyectos I+D
Call year 2011
State Plan 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Management unit Subdirección General de Proyectos de Investigación
Beneficiary centre AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publication Artículo científico (JournalArticle)

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

  • Robles, Eloy F.
  • Bellosillo Paricio, Beatriz
  • Salar, Antonio
  • Martinez-Climent, Jose A.
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2-3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. While Nkx2-3-deficient mice exhibit the absence of marginal-zone B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that leads to the development of tumours, faithfully recapitulating the principal clinical and biological features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhesion molecules (ICAM-1, MadCAM-1) and the chemokine receptor CXCR4. These molecules enhance migration, polarization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transformation through triggering NF-κB and PI3K-AKT pathways. This study implicates oncogenic NKX2-3 in lymphomagenesis, and provides a valid experimental mouse model for studying the biology and therapy of human marginal-zone B-cell lymphomas., This work was supported by Grants from the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness, FIS-PI12/00202 (to J.A.M.-C.), RTICC-RD12/0036/0063 (to J.A.M-C.), RTICC-RD12/0036/0068 (to M.J.C and F.P.), RTICC-RD12/0036/0022 (to J.L.F-L.), RTICC-RD12/0036/0070 (to J.C.), RTICC-RD12/0036/0010 (to B.B.), RTICC- RD12/0036/0044 (to M.J.B.) and RTICC-RD12/0036/0069 (to J.M.H.R. and M.G.); by Worldwide Cancer Research project grant 15-1322 (to J.A.M.-C., Y.R.C. and M.-Q.D.); by BFU2011-30097 (to Y.R.C); by MINECO SAF2013-45787-R and Marie Curie Programme FP7-PIIF-2012-328177 (to S.R.); by the French-Spanish CITTIL project (to F.P., X.A., J.A.M.-C., C.B. and P. Brousset); by SAF2012-32810, SAF2014-57791-REDC; PIE14/00066, BIO/SA32/14 and CSI001U14 (to I.S.G); by FIS-ISCIII projects PI13/00160 and PI14/00025, and Fundación Inocente Inocente (to C.C.); by Deutsche Krebshilfe, Molecular Mechanisms in Malignant Lymphomas Network Project (to R.S.); by the Institut Universitaire de France (to P. Brousset); by the Broad Medical Research Program of The Eli and Edythe Broad Foundation and the Hungarian Scientific Research Fund (OTKA K108429) (to P. Balogh); by pre- and post-doctoral fellowships from the Foundation for Applied Medical Research (to M.M.V. and E.F.R., respectively); and by a post-doctoral fellowship from the Basque Government (to I.M.-G.). All Spanish funding is co-sponsored by theEuropean Union FEDER program
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics.

  • Robles, Eloy F.
  • Bellosillo Paricio, Beatriz
  • Salar, Antonio
  • Martinez-Climent, Jose A.
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2-3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. While Nkx2-3-deficient mice exhibit the absence of marginal-zone B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that leads to the development of tumours, faithfully recapitulating the principal clinical and biological features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhesion molecules (ICAM-1, MadCAM-1) and the chemokine receptor CXCR4. These molecules enhance migration, polarization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transformation through triggering NF-κB and PI3K-AKT pathways. This study implicates oncogenic NKX2-3 in lymphomagenesis, and provides a valid experimental mouse model for studying the biology and therapy of human marginal-zone B-cell lymphomas., This work was supported by Grants from the Instituto de Salud Carlos III (ISCIII), Spanish Ministry of Economy and Competitiveness, FIS-PI12/00202 (to J.A.M.-C.), RTICC-RD12/0036/0063 (to J.A.M-C.), RTICC-RD12/0036/0068 (to M.J.C and F.P.), RTICC-RD12/0036/0022 (to J.L.F-L.), RTICC-RD12/0036/0070 (to J.C.), RTICC-RD12/0036/0010 (to B.B.), RTICC- RD12/0036/0044 (to M.J.B.) and RTICC-RD12/0036/0069 (to J.M.H.R. and M.G.); by Worldwide Cancer Research project grant 15-1322 (to J.A.M.-C., Y.R.C. and M.-Q.D.); by BFU2011-30097 (to Y.R.C); by MINECO SAF2013-45787-R and Marie Curie Programme FP7-PIIF-2012-328177 (to S.R.); by the French-Spanish CITTIL project (to F.P., X.A., J.A.M.-C., C.B. and P. Brousset); by SAF2012-32810, SAF2014-57791-REDC; PIE14/00066, BIO/SA32/14 and CSI001U14 (to I.S.G); by FIS-ISCIII projects PI13/00160 and PI14/00025, and Fundación Inocente Inocente (to C.C.); by Deutsche Krebshilfe, Molecular Mechanisms in Malignant Lymphomas Network Project (to R.S.); by the Institut Universitaire de France (to P. Brousset); by the Broad Medical Research Program of The Eli and Edythe Broad Foundation and the Hungarian Scientific Research Fund (OTKA K108429) (to P. Balogh); by pre- and post-doctoral fellowships from the Foundation for Applied Medical Research (to M.M.V. and E.F.R., respectively); and by a post-doctoral fellowship from the Basque Government (to I.M.-G.). All Spanish funding is co-sponsored by theEuropean Union FEDER program
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics

  • Robles, Eloy F.
  • Mena-Varas, Maria
  • Barrio, Laura
  • Merino-Cortes, Sara V.
  • Balogh, Péter
  • Du, Ming-Qing
  • Akasaka, Takashi
  • Parker, Anton
  • Roa, Sergio
  • Panizo, Carlos
  • Martin-Guerrero, Idoia
  • Siebert, Reiner
  • Segura, Victor
  • Agirre, Xabier|||0000-0002-6558-9560
  • Macri-Pellizeri, Laura
  • Aldaz, Beatriz
  • Vilas-Zornoza, Amaia|||0000-0001-6693-0989
  • Zhang, Shaowei
  • Moody, Sarah
  • Calasanz, M.J.|||0000-0002-0374-3008
  • Tousseyn, Thomas
  • Broccardo, Cyril
  • Brousset, Pierre
  • Campos-Sanchez, Elena
  • Cobaleda, Cesar|||0000-0003-3807-9204
  • Sánchez García, Isidro
  • Fernandez-Luna, Jose Luis
  • Garcia-Muñoz, Ricardo
  • Pena, Esther
  • Bellosillo Paricio, Beatriz|||0000-0002-5335-2726
  • Salar Silvestre, Antonio|||0000-0002-4652-4825
  • Baptista, Maria Joao|||0000-0003-3471-2535
  • Hernández Rivas, Jesús María|||0000-0002-9661-9371
  • González, Marcos
  • Terol, Maria Jose|||0000-0002-9467-932X
  • Climent Bataller, Joan|||0000-0002-8927-6614
  • Ferrandez, Antonio
  • Sagaert, Xavier
  • Melnick, Ari M.
  • Prosper, Felipe|||0000-0001-6115-8790
  • Oscier, David G.
  • Carrasco, Yolanda R.
  • Dyer, Martin J. S.
  • Martinez-Climent, Jose A.
NKX2 homeobox family proteins have a role in cancer development. Here we show that NKX2 - 3 is overexpressed in tumour cells from a subset of patients with marginal-zone lymphomas, but not with other B-cell malignancies. While Nkx2-3 -deficient mice exhibit the absence of marginal-zone B cells, transgenic mice with expression of NKX2-3 in B cells show marginal-zone expansion that leads to the development of tumours, faithfully recapitulating the principal clinical and biological features of human marginal-zone lymphomas. NKX2-3 induces B-cell receptor signalling by phosphorylating Lyn/Syk kinases, which in turn activate multiple integrins (LFA-1, VLA-4), adhesion molecules (ICAM-1, MadCAM-1) and the chemokine receptor CXCR4. These molecules enhance migration, polarization and homing of B cells to splenic and extranodal tissues, eventually driving malignant transformation through triggering NF-κB and PI3K-AKT pathways. This study implicates oncogenic NKX2-3 in lymphomagenesis, and provides a valid experimental mouse model for studying the biology and therapy of human marginal-zone B-cell lymphomas. The homeobox NKX2 family of transcriptional factors has been shown to regulate fundamental developmental processes. Here, the authors show that NKX2-3 is a bona fide oncogenic driver in marginal-zone B-cell lymphoma and that it promotes lymphomagenesis by shaping lymphocyte dynamics and promoting BCR signalling.